IP Library Granted Patent US 9,226,920
Granted Patent B1
US 9,226,920 · App. 12/137,795 · Granted Jan 5, 2016

Methods of inducing and preventing neurofibromatosis in Schwann cells

Inventors: Cristina Fernandez-Valle (Oviedo, FL); Courtney Thaxton (Orlando, FL); Jorge Lopera (Orlando, FL); Marga Bott (Oviedo, FL)
Assignee: University of Central Florida Research Foundation, Inc.
A61K31/43
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,226,920
App. No.
12/137,795
Granted
Jan 5, 2016
Kind
B1
Abstract

The invention provides a method of inducing neurofibromatosis type 2 (NF2) in Schwann cells. The method comprises contacting the cells with laminin-1 so as to bind α6β1 integrin sufficiently to activate endogenous kinase Cdc42-Pak; and phosphorylating Schwannomin-S518 in the cells by the activated kinase, effectively inactivating Schwannomin's tumor suppressor activity and allowing proliferation of subconfluent Schwann cells, thereby modeling NF2. The invention also includes a method of preventing a Schwann cell from forming a tumor by contacting the cell with an amount of tyrphostin AG825 sufficient to inhibit a receptor selected from ErB2, ErB3, β1 integrins and combinations thereof, so as to prevent phosphorylation of Schwannomin-S815 by one or more endogenous kinases.

Claims (7)

1. A method of circumventing a lack of neurofibromatosis type 2 tumor suppressor activity in Schwann cells, the method comprising:

contacting Schwann cells lacking neurofibromatosis type 2 suppressor activity with an effective amount of tyrphostin AG825 that inhibits normal function of a receptor selected from the group consisting of ErbB2, ErbB3, β1 integrins and combinations thereof;

wherein the contacting prevents the cells from receiving a growth signal normally inhibited by a neurofibromatosis type 2 tumor suppressor, and

wherein the Schwann cells comprise a mutated Schwannomin protein that causes the Schwann cells to lack neurofibromatosis type 2 suppressor activity.

2. A method of preventing a Schwann cell from forming a tumor associated with neurofibromatosis type 2, the method comprising:

contacting a Schwann cell lacking neurofibromatosis type 2 suppressor activity with an amount of tyrphostin AG825 sufficient to inhibit a receptor selected from the group consisting of ErbB2, ErbB3, β1 integrins and combinations thereof, wherein the contacting prevents the cell from receiving a growth signal normally inhibited by a neurofibromatosis type 2 tumor suppressor, and

wherein the Schwann cells comprise a mutated Schwannomin protein that causes the Schwann cells to lack neurofibromatosis type 2 suppressor activity.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 3, 2013
From: UNIVERSITY OF CENTRAL FLORIDA
To: US ARMY, SECRETARY OF THE ARMY
Reel/Frame 031753/0882 →
NUNC PRO TUNC ASSIGNMENT Recorded Jul 22, 2008
From: FERNANDEZ-VALLE, CRISTINA; BOTT, MARGA; THAXTON, COURTNEY; LOPERA, JORGE
To: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
Reel/Frame 021272/0484 →
Continuity (2)
Provisional Application 60946782 · Jun 28, 2007
Provisional Application 60955141 · Aug 10, 2007